Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer [0.03%]
Chiara Corti,Tianyu Li,Alyssa R Martin et al.
Chiara Corti et al.
Background: Pathologic complete response (pCR) after neoadjuvant treatment (NAT) is prognostic for recurrence-free survival (RFS) and overall survival (OS) in breast cancer (BC). We assessed prognostic factors for RFS and...
Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02) [0.03%]
Mark Opdam,Nigel Ultee,Jill J J Geenen et al.
Mark Opdam et al.
Background: Intensified anthracycline-based regimens are as effective as standard anthracycline-based chemotherapy with taxanes in unselected high-risk patients with early breast cancer and come with their own toxicity pr...
A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer [0.03%]
Nadine S van den Ende,Marcel Smid,John W M Martens et al.
Nadine S van den Ende et al.
Around half of triple negative breast cancer (TNBC) patients achieve a pathological complete response (pCR) based on neoadjuvant chemotherapy (NAC), which is associated with a good outcome. Conversely, in patients with a poor response to NA...
Sentinel lymph node detection in early-stage breast cancer - Are technetium-99m-nanocolloid and superparamagnetic iron oxide diagnostically equivalent procedures? A propensity score matched real world data analysis [0.03%]
Ina Shehaj,Katharina Stuppy,Amelie Löwe et al.
Ina Shehaj et al.
Several studies have compared validated tracers, such as the radioactive tracer technetium-99m nanocolloid (99mTc-nanocolloid) and superparamagnetic iron oxide (SPIO), for sentinel node biopsy (SNB) in early-stage breast cancer (eBC). These...
Paola Zagami,Beatrice Taurelli Salimbeni,Eleonora Petra Preti et al.
Paola Zagami et al.
Background: The diagnosis and treatment of breast cancer (BC) can significantly impact patients' sexual and psycho-physical wellbeing. Awareness and preparedness among healthcare professionals are essential to address the...
Effect of adjuvant endocrine therapy on recurrence and contralateral breast cancer in HR-positive DCIS after mastectomy [0.03%]
Tae-In Yoon,Ah Yoon Kim,Su Min Lee et al.
Tae-In Yoon et al.
Background: The clinical benefits of adjuvant endocrine therapy for patients with hormone receptor (HR)-positive ductal carcinoma in situ (DCIS) undergoing mastectomy remain controversial. While endocrine therapy is known...
Modification of RECIST 1.1 criteria for assessing response in breast tumours treated with radiation therapy using multiparametric breast MRI: Radiology and oncology perspective [0.03%]
E Durie,M Morris,N A Healy et al.
E Durie et al.
The traditional, size-based, RECIST 1.1 guideline is the standard for assessing tumour response, but has notable limitations, particularly for breast tumours treated with radiotherapy (RT). RT often induces fibrosis, leading to a persisting...
External validation of a data-driven algorithm to identify breast cancer recurrences from administrative healthcare data [0.03%]
Silvia Mancini,Fabiola Giudici,Lauro Bucchi et al.
Silvia Mancini et al.
Introduction: Population-based data on the incidence of breast cancer (BC) recurrence are scarce, because tracking the relevant information is resource-consuming. We report the external validation of a data-driven case-fi...
Histopathological evaluation of local effects of radioactive iodine seeds in axillary lymph nodes in clinically node-positive breast cancer treated with neoadjuvant systemic therapy [0.03%]
新辅助系统治疗后临床阳性腋窝淋巴结乳腺癌患者放射性碘粒子组织病理学评价
Florien J G van Amstel,Janine M Simons,Loes Kooreman et al.
Florien J G van Amstel et al.
Background: In clinically node-positive (cN+) patients, radioactive iodine (125I) seeds can be considered to mark metastatic axillary lymph nodes before neoadjuvant therapy (MARI-procedure) but potential therapeutic effec...